ABOUT
Eye conditions on the rise
Reality & numbers
2.2 billion people suffer from vision impairments of which 50% could be prevented or cured according to the World Health Organization. This number is growing due to our ageing populations and modern lifestyles.
Current testing standards are not fit for the 21st century. They require stationary and resource-intense workflows and often produce limited insights. This leads to bottlenecks in clinics and limited patient access to eye testing & adequate treatment.
ABOUT
Our mission
@Perivision
We want to change that and make eye testing & care accessible to everyone - everywhere. For this, PeriVision combines artificial intelligence (AI), virtual reality (VR) and the cloud to build the next generation systems to test and understand visual function.
2017
1st peer-reviewed publication on AI-based fast perimetry
2018
Clinical study to validate AI-based fast-perimetry algorithm
2020
Clinical study on VR-based perimetry concluded
2021
Winning EIT Health Wild Card accelerator
2022
PeriVision SA incorporated & patents granted
2023
To be completed by something
2024
FDA registration of VisionOne platform
INATEC AG
Our investors
Our story
2017
1st peer-reviewed publication on AI-based fast perimetry
2018
Clinical study to validate AI-based fast-perimetry algorithm
2020
Clinical study on VR-based perimetry concluded
2021
Winning EIT Health Wild Card accelerator
2022
PeriVision SA incorporated & patents granted
2023
PeriVision USA incorporated
2024
VisionOne™ platform available in US, UK & EU
Founders, board & management
Patrick Kessel
Co-founder, CEO & board member
Strategy consultant-turned-entrepreneur with a passion for healthcare innovation
Patrick Kessel holds a B.A. in Business Administration from the University of St. Gallen (HSG), including an exchange semester at Singapore Management University (SMU), and a MSc. in Political Science (Distinction) from the London School of Economics & Political Science (LSE). He is also a certified Scrum Master. Prior to joining PeriVision, he advised medtech, biopharma and insurance clients on business development, go-to-market strategy, digitization and operations optimization at the Boston Consulting Group (BCG). While at BCG, he initiated the firm’s tech startup support program “BCG Startup Unlock” to provide pro-bono strategy consulting to Swiss technology startups.
Dr. Serife Kucur Ergunay
Co-founder, CTO & board member
Award-winning AI researcher pushing the boundaries of vision care
Dr. Serife Kucur Ergunay holds a BSc. in Telecommunication Engineering from Istanbul Technical University, a MSc. in Information & Communication Technologies from École polytechnique fédérale de Lausanne (EPFL) where she obtained an EPFL Excellence Scholarship for Master Studies. She then obtained a PhD. in Biomedical Engineering from the ARTORG Center for Biomedical Engineering at the University of Bern. During more than six years of PhD. and post-doctoral research, she focused on applying AI to ophthalmology and perimetry data. For her translational research she has been granted a BRIDGE proof-of-concept grant by the Swiss National Science Foundation (SNCF). She has published multiple journal articles with leading clinicians and perimetry experts and presented her innovations at high-caliber scientific conferences such as the annual meetings of the Association for Research in Vision and Ophthalmology (ARVO) and the International Perimetry Society (PIS).
Prof. Dr. Raphael Sznitman
Co-founder & board member
Professor and serial entrepreneur at the intersection of AI and medicine
Prof. Dr. Raphael Sznitman holds a BSc. in Cognitive Systems in Computational Intelligence from the University of British Columbia and a MSc. and PhD. in Computer Science from John Hopkins University. He was a post-doctoral researcher at École polytechnique fédérale de Lausanne and is currently serving as Director of the ARTORG Center for Biomedical Engineering Research and the Center for AI in Medicine at the University of Bern. He has more than fifteen years of experience in AI solutions in health care and ophthalmology. He is also a co-founder and scientific advisor for RetinAI Medical AG, a Swiss AI and ophthalmology startup, acquired by Essilor-Luxottica.
Kevin Gillmann
Chief Medical Officer
Ophthalmologist & glaucoma specialist with international clinical & research experience across the UK, US and Switzerland and 50+ peer-reviewed publications
Kevin Gillmann graduated from Newcastle University Medical School and earned his MD on Minimally-Invasive Glaucoma Surgery from the University of Lausanne. He also holds an MBA with Distinction from the University of London, a PhD from Kingston University, a post-graduate certificate in Media & Medicine from Harvard Medical School, and a Master of Architecture from the University of Paris LaVillette. His expertise spans across Europe and the United States, where he has held key positions, including Honorary Fellow at Moorfields Eye Hospital and Medical Director at Genève Ophtalmologie. With over 50 peer-reviewed publications and 850 citations, he is the editor of Elsevier’s glaucoma textbook «The Science of Glaucoma Management», and is a lecturer at the University of London.
MD. PhD. MBBS. MBA. FEBO. MCMI. MArch. PgCert
Benedetto Sgroi
Chief Commercial Officer
Senior commercial executive with 30 years experience across ophthalmology medtech, biotech & pharma; SOI 2022 award for a life spent serving ophthalmology.
Benedetto Sgroi is a highly qualified senior executive with over 30 years of experience in international business development, strategic marketing and sales management. He possesses an unrivaled talent for proactively identifying new products and companies, guiding them from concept to market entry and beyond. Benedetto's extensive knowledge in the field of ophthalmology spans across glaucoma, cornea, cataract, refractive surgery and retina. He is experienced in driving product, process and customer service improvements, while building and motivating cross-functional teams to drive growth across territories with new international product lines, expanding with first-class distributors, multinational companies and biopharma corporations. He has achieved exceptional results in highly competitive environments that demand continuous improvement. Prior to joining PeriVision, he was CEO at Oftalmedica, a leading Italian ophthalmology medtech distributor, Sales Manager Central EU for Avedro (USD 100M NASDAQ IPO, USD 400M acquisition by Glaukos), VP International Sales & Marketing at Avellino Lab (NASDAQ IPO exp. in Q4 2024) and Global Head of Business Development, Sales & Marketing at EarlySight. Benedetto is also a recipient of the SOI 2022 award for a life spent serving ophthalmology, the highest ophthalmic industry recognition in Italy.
Dr. Ernest Cavin
Board member
Seasoned C-Level executive and experienced independent board director, leveraging his global business acumen in the ophthalmology sector to drive technological and healthcare advancements.
Ernest Cavin holds a BSc in Microelectronics/Micromechanics from the Bern University of Applied Sciences, an MBA from City University Seattle (WA), and a PhD in Business Administration from Argosy University (IL). He was very successful as the Vice President of International Sales at Ziemer Ophthalmic Systems, achieving record sales in the company's history. He has also previously held the positions of CEO & President at Haag-Streit USA and Reliance Medical Products, renowned manufacturers of ophthalmic devices. In addition, he has contributed as a board member at Comlab, a company at the forefront of high-frequency technology and digital communication systems for trains. Ernest Cavin also serves on the board of Clovernook, a non-profit organization dedicated to assisting the blind and visually impaired. His commitment to advancing medical technology and healthcare extends to his past role on the panel committee of Glaucoma 360, the oldest and most experienced non-profit institution in America focused on curing glaucoma and restoring vision through groundbreaking research.
Arijana Walcott
Board member
Co-founder & managing partner of DART Ventures, empowering EU deep-tech founders to thrive in the US market.
Through DART, she invests in early-stage Health and Climate Tech startups from Switzerland and Europe, helping them access the US market. She also serves as a Board Member at the Swiss Startup Association and the fundraising platform Oomnium, while actively organizing the SwissVC Community.
Sanem Tatlıdil Özal
Board observer
General Partner at Arya VC; VC investor with over 25 years of experience in finance, venture capital, and international business development; active angel investor in tech startups.
Sanem Tatlıdil Özal holds a Bachelor’s degree in Business Administration from Middle East Technical University (METU) and an MBA from NYU Stern School of Business. She began her career in finance and risk management at KoçSistem Turkey, before moving to New York to invest in early-stage technology startups at a VC fund. She later joined UBS’s portfolio management team, overseeing a $5 billion portfolio. After returning to Turkey, she established the International Business Development unit at Garanti Bank, forging strategic partnerships with BBVA and BlackRock. For the past decade, she has been an active angel investor in technology startups. With over 25 years of experience in investment and finance, she brings deep expertise in building cross-border partnerships, managing large portfolios, and supporting high-growth companies.
Advisors
Prof. Dr. Dr. Martin Zinkernagel
Clinical advisor
.png)
Dr. Paolo Brusini
Clinical advisor
Dr. Bobby Tang, MD MPH
Clinical advisor
Prof. Robert Weinreb, MD
Clinical advisor
Mark Lesselroth
Business advisor
Katrin Siebenbuerger Hacki
Business advisor
Stefan Tuchschmid, PhD
Business advisor
Eric Evans
Business advisor
ABOUT US
Our mission
2.2 billion people suffer from vision impairments of which 50% could be prevented or cured according to the World Health Organization. This number is growing due to our ageing populations and modern lifestyles.
Current testing mechanisms are not fit for the 21st century. They run on bulky devices, require stationary and expensive workflows and often produce limited insights.
At Perivision, we combine artificial intelligence (AI), virtual reality (VR) and the cloud to build the next generation systems to understand visual function. Our systems improve workflow efficiency in practices and hospitals and provide deeper clinical insight into eye diseases.
Join PeriVision
No open positions at the moment
PeriVision · Lausanne
We’re always happy to hear from talented people who share our vision. If you think you’d be a great fit, feel free to send us your CV and a short message, we'll see if there's any good fits in the future.